Tango Therapeutics, Inc. (TNGX)

Mixed fundamental profile for this clinical-stage precision oncology biotech: an exceptionally strong balance sheet (about $1.0 billion of cash and marketable securities versus roughly $49 million of total liabilities and no debt) sits against a deeply negative earnings picture (no product revenue, $0 collaboration revenue in 2026 after the Gilead research-term truncation, widening losses, TTM net margin around -230%, and negative DCF values). SEC filings show no going-concern warning, no debt covenants, a clean audit, and sufficient liquidity for years of runway. Street sentiment is bullish (consensus target $45.91 vs $23.87) on strong vopimetostat/RAS(ON) combination data and a planned Phase 3 in MTAP-deleted pancreatic cancer, but sales-based valuation is very rich, dilution has been heavy, and insiders have been net sellers. The fundamentals are genuinely mixed: low financial risk and catalyst-rich, but absent earnings and elevated equity/clinical risk.

No actionable catalyst inside the 1–30 day horizon: the Q2 2026 print (92% ORR vopimetostat + daraxonrasib pancreatic data, $1.0B cash) is 29 days trailing and digested, leaving only routine PRs, valuation-stretch commentary, and 10b5-1 insider sales in the scoring window; the sentiment delta is flat-to-cooling (baseline ≈ +0.05 → scoring ≈ 0.0, thin degraded samples), retail is absent, and the Red-Flag Screen is clean — an Absent setup with no cap fired.

Mixed chart: price sits below SMA20 (24.14), SMA50 (26.74) and EMA21 (24.27), but above SMA200 (19.75) and EMA9 (23.30). RSI14 45.09 has recovered from ~33 on 2026-09-02, Williams %R -58.37 is off oversold, and MACD printed a fresh bullish cross (line -1.10 vs signal -1.11, histogram +0.01) below zero; ADX14 17.96 shows no trend strength. The 2026-09-09 +5.5% high-volume bounce off the ~$22 support shelf visually resembles an early oversold_reversal, but the intermediate trend is still down and the setup is unconfirmed. Score capped at 2 by the stale-feed gate: this partial run provides no run-date source (runDate absent, cached=true), so the read cannot be anchored as a current market read; qualitativeScore 2 independently blocks any trade.